Astrazeneca Plc (AZN)
$44.34
0.16 (0.36%)
AZN Stock Quote Delayed 15 Minutes
Previous Close
$44.34
Market Cap
112.33B
PE Ratio
40.02
EPS
1.107848
Volume (Avg. Vol.)
1.50M
Day's Range
44.29 - 44.55
52-Week Range
35.30 - 45.28
Dividend & Yield
1.37 (3.09%)
AZN Stock Predictions, Articles, and Astrazeneca Plc News
New Sanofi CEO 2019: 8 Things to Know About Paul Hudson
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.
Is AstraZeneca Stock Worth Buying Before Earnings?
AZN stock is great to own, but you should choose your entry points carefully, as AstraZeneca has some short-term risks ahead.
3 Big Stock Charts for Monday: L Brands, Progressive and Packaging Corp. of America
The stock charts of PGR, LB and PKG are going to start the new trading week on the cusp of major moves that have been forming for weeks.
AstraZeneca News: Why AZN Stock Is Sliding Lower Today
AstraZeneca announced that it has inked a deal with Daiichi Sankyo to improve its oncology branch. AZN stock is down more than 5% on Friday.
AstraZeneca Earnings: AZN Stock Zooms Higher on Q4 Beat
An AstraZeneca earnings beat for the pharmaceutical company's fourth quarter of 2018 has AZN stock heading higher on Thursday.
This Health Care Stock Could Pay Off Big
Today I am recommending a bullish trade on AstraZeneca PLC (NYSE:AZN), a biopharmaceutical company focused on the development, discovery and commercialization of prescription medicines for a variety of diseases.
The Outlook for AstraZeneca Is Positive, But It’s Too Early to Pull the Trigger
AstraZeneca's profits are poised to accelerate, but investors should wait for AZN stock to break out of its range before buying the shares.
Biogen Is the Right Alzheimer’s Stock … At the Wrong Time
BIIB stock jumped on Friday, and for good reason. It's not a buy at these lofty levels, but Biogen has at least earned a spot on your watchlist.
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
AstraZeneca plc Stock Slips on Q1 Earnings Miss, Falling Crestor Sales
AstraZeneca plc (AZN) stock was down on Friday following the release of its earnings report for the first quarter of 2018.
The Future of Merck & Co., Inc. Stock Is With Keytruda
Merck & Co's cancer drug, Keytruda, saw explosive growth this quarter, making MRK stock a tough name to handicap right now.
AstraZeneca’s (AZN) Solid Earnings Visibility Keep it a Buy
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Buy. With unique fundamental and quantitative metrics developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. The current Portfolio Grader recommendation on the shares has been in place for the last month.
Earnings Visibility Make AstraZeneca (AZN) a Buy
AstraZeneca Plc (NYSE:AZN) is a $83.3 billion in market value constituent of the Pharmaceuticals GICS industry group where the ranking for AZN by Portfolio Grader places it 37 among the 132 companies in this industry group, giving it an above-average position. AZN is ranked in the top half of the sector with a ranking of 267 among the 782 companies in the sector and number 1,662 in the 5000 company Portfolio Grader company universe.
AstraZeneca (AZN) Upgraded to Buy on Strong Quant Score
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Buy. The methodology for investing incorporated in this analytical tool developed by Louis Navellier researches and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.
AstraZeneca (AZN) Upgraded to Buy from a Hold
AstraZeneca Plc (NYSE:AZN) is ranked as a Buy using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methods. The shares have been upgraded from a Hold to a Buy in the last week.
Earnings Growth Restricts AstraZeneca (AZN) Rating
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Hold. Using Louis Navellier's investing methodology, this analytical tool assesses stocks with fundamental and quantitative analytical tools. AZN has maintained this ranking for the last month.
Quant Score Restricts AstraZeneca (AZN) Rating
AstraZeneca Plc (NYSE:AZN) is a component of the 135 company Pharmaceuticals GICS industry group, which is a segment of the 783 company GICS Health Care sector. AZN's market value is $87.6 billion which falls in the top decile in its industry group. The ranking for AZN by Portfolio Grader places it 49 among the 135 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 301 among the 783 companies in the sector, and number 2,076 in the nearly 5,000 company Portfolio Grader universe.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
